Prothena Corporation plc is a clinical-stage
         biotechnology company with a portfolio of
      novel monoclonal antibodies that may offer new
   treatments for diseases associated with protein
misfolding or cell adhesion.

LATEST NEWS

SPOTLIGHT

Potential Mechanism of Action (MOA) Videos:

vid_neod001
for Amyloidosis
vid_prx002
for Parkinson’s Disease
vid_prx003
for Inflammatory Diseases
and Cancers

thumbnail-bloomberg-daleCEO Dale Schenk discusses Prothena’s proprietary programs with Bloomberg TV
Discusses development of treatments for Alzheimer’s and Parkinson’s diseases with Olivia Sterns on Bloomberg’s “In the Loop”.  June 6, 2013